We are happy to announce that PVpharm have enter in a new agreement with Leiden University Medical Center (LUMC) to provide safety and regulatory consulting. LUMC was formed from a collaboration between the Academic Hospital Leiden and the Faculty of Medicine of Leiden University, and provides scientific and material support to first steps of the drug development in humans.
As an innovator, the LUMC stands for improving healthcare and people’s health. This is done on the basis of leading research and innovative education. The objective of the LUMC is to be one of the top 10 University Medical Centers in Europe.
Our collaboration will focus on helping about EMA’s Clinical Trial Information System (CTIS) and pharmacovigilance tasks, including XEVMPD management and SUSAR submissions to Eudravigilance, essential in these steps of drug development.
PVpharm provides services in all the phases of the medicinal product life cycle, and we have different services for sponsors of clinical trials in the EU. For more information, please read more at https://pvpharm.com/pharmacovigilance/
Please contact us with any question https://pvpharm.com/contact/